Edesa Biotech, Inc. EDSA
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.08% | 25.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 28.45% | 83.52% | |||
| Operating Income | -28.45% | -83.52% | |||
| Income Before Tax | -28.22% | -87.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -28.19% | -87.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.19% | -87.67% | |||
| EBIT | -28.45% | -83.52% | |||
| EBITDA | -28.63% | -84.43% | |||
| EPS Basic | -21.54% | -75.20% | |||
| Normalized Basic EPS | -21.58% | -75.14% | |||
| EPS Diluted | -21.54% | -75.20% | |||
| Normalized Diluted EPS | -21.58% | -75.14% | |||
| Average Basic Shares Outstanding | 5.46% | 7.13% | |||
| Average Diluted Shares Outstanding | 5.46% | 7.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||